Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00017459 | Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | PHASE3 | COMPLETED | - | — | — | Jul 1, 2000 | Feb 1, 2004 | Aug 2, 2013 | 42 | United States |
| Name | Type | Description |
|---|---|---|
| cisplatin | DRUG | - |
| tirapazamine | DRUG | - |
| vinorelbine tartrate | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) Stage IIIB or IV Newly diagnosed or recurrent disease Measurable lesions At least 10 mm by spiral CT scan OR At least 20 mm by conventional techniques Previously irradiated lesions are considered me...